Oxford Science Enterprises and Cedars-Sinai Intellectual Property Company invest $2 million in Neu Health to co-develop and expand digital neurology care solutions in the US and UK markets.

Target Information

Neu Health, a start-up emerging from the University of Oxford, specializes in a digital smartphone-based neurology care platform aimed at enhancing patient outcomes for individuals affected by Parkinson's disease and dementia. The platform integrates unique data and artificial intelligence to convert motor and non-motor symptoms, as well as cognitive and mental health metrics, into objective insights that can be effectively utilized by clinicians.

Recently, Neu Health has gained traction in the UK healthcare market, demonstrating a tangible impact on patient satisfaction and the quality of care provided. With a solid foundation backed by extensive research from Oxford experts, Neu Health is poised to expand its reach into the U.S. market through strategic partnerships.

Industry Overview

The health-tech sector in both the UK and the US has witnessed significant growth in recent years, driven by advancements in technology and a heightened focus on patient-centered